TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3010% above fair value
$66.12+3.41 (+5.44%)
Close on Nov 18, 2026Market cap $10.12BP/E 24.1Yield –
TG Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
TG Therapeutics's operating income for the twelve months ending Jun 30, 2026 was $136.33M, up 58.8% year over year. For fiscal 2025 it was $123.32M, up 194.1% from the year before. The highest annual figure on record is $123.32M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $123.32M | +194.1% |
| FY2024 | Dec 31, 2024 | $41.93M | +103.2% |
| FY2023 | Dec 31, 2023 | $20.63M | – |
| FY2022 | Dec 31, 2022 | -$218.32M | – |
| FY2021 | Dec 31, 2021 | -$344.77M | – |
| FY2020 | Dec 31, 2020 | -$273.59M | – |
| FY2019 | Dec 31, 2019 | -$169.06M | – |
| FY2018 | Dec 31, 2018 | -$174.40M | – |
| FY2017 | Dec 31, 2017 | -$118.71M | – |
| FY2016 | Dec 31, 2016 | -$78.97M | – |
| FY2015 | Dec 31, 2015 | -$63.18M | – |
| FY2014 | Dec 31, 2014 | -$55.72M | – |
| FY2013 | Dec 31, 2013 | -$22.97M | – |
| FY2012 | Dec 31, 2012 | -$26.90M | – |
| FY2011 | Dec 31, 2011 | -$881.97K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $21.67M | -37.8% |
| Q1 FY2026 | Mar 31, 2026 | $34.80M | +303.6% |
| Q4 FY2025 | Dec 31, 2025 | $50.49M | +68.6% |
| Q3 FY2025 | Sep 30, 2025 | $29.37M | +136.2% |
| Q2 FY2025 | Jun 30, 2025 | $34.84M | +295.2% |
| Q1 FY2025 | Mar 31, 2025 | $8.62M | – |
| Q4 FY2024 | Dec 31, 2024 | $29.95M | – |
| Q3 FY2024 | Sep 30, 2024 | $12.43M | -89.2% |
| Q2 FY2024 | Jun 30, 2024 | $8.82M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.27M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.49M | – |
| Q3 FY2023 | Sep 30, 2023 | $114.78M | – |
| Q2 FY2023 | Jun 30, 2023 | -$44.67M | – |
| Q1 FY2023 | Mar 31, 2023 | -$36.99M | – |
| Q4 FY2022 | Dec 31, 2022 | -$77.54M | – |
| Q3 FY2022 | Sep 30, 2022 | -$34.96M | – |
| Q2 FY2022 | Jun 30, 2022 | -$38.94M | – |
| Q1 FY2022 | Mar 31, 2022 | -$66.87M | – |
| Q4 FY2021 | Dec 31, 2021 | -$92.95M | – |
| Q3 FY2021 | Sep 30, 2021 | -$85.13M | – |
| Q2 FY2021 | Jun 30, 2021 | -$77.49M | – |
| Q1 FY2021 | Mar 31, 2021 | -$89.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$86.78M | – |
| Q3 FY2020 | Sep 30, 2020 | -$85.72M | – |
| Q2 FY2020 | Jun 30, 2020 | -$50.85M | – |
| Q1 FY2020 | Mar 31, 2020 | -$50.25M | – |
| Q4 FY2019 | Dec 31, 2019 | -$37.96M | – |
| Q3 FY2019 | Sep 30, 2019 | -$60.86M | – |
| Q2 FY2019 | Jun 30, 2019 | -$35.54M | -180.2% |
| Q1 FY2019 | Mar 31, 2019 | -$34.69M | – |
| Q4 FY2018 | Dec 31, 2018 | -$54.15M | – |
| Q3 FY2018 | Sep 30, 2018 | -$34.33M | – |
| Q2 FY2018 | Jun 30, 2018 | $44.35M | – |
| Q1 FY2018 | Mar 31, 2018 | -$41.58M | – |
| Q4 FY2017 | Dec 31, 2017 | -$31.04M | – |
| Q3 FY2017 | Sep 30, 2017 | -$31.59M | – |
| Q2 FY2017 | Jun 30, 2017 | -$28.43M | – |
| Q1 FY2017 | Mar 31, 2017 | -$27.67M | – |
| Q4 FY2016 | Dec 31, 2016 | -$24.03M | – |
| Q3 FY2016 | Sep 30, 2016 | -$24.93M | – |
See a number that looks wrong?